Home Newsfeeds Credit Suisse Maintains Outperform on TransDigm Gr, Raises Price Target to $765

Credit Suisse Maintains Outperform on TransDigm Gr, Raises Price Target to $765

Credit Suisse analyst Scott Deuschle maintains TransDigm Gr (NYSE:TDG) with a Outperform and raises the price target from $735 to $765.

byBenzinga Newsdesk

February 1, 2023

1 minute read

Credit Suisse analyst Scott Deuschle maintains TransDigm Gr (NYSE:TDG) with a Outperform and raises the price target from $735 to $765.

Why Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

February 8, 8:44 AM

Shares of The Walt Disney Company (NYSE: DIS) rose in today’s pre-market trading following the release of quarterly results.

AEY

Nvidia CEO Jensen Huang Mesmerizes Analysts, Market Watchers With Computex Keynote: ‘Will Make You Want To Buy $NVDA’

By Shanthi Rexaline

June 3, 3:11 AM

Calling computer graphics, simulations, and AI "the soul of Nvidia," Huang said these are put together in a virtual world called Omniverse.

NVDA

News

Mineralys Therapeutics Announced JAMA Publication Of Full Target-HTN Phase 2 Trial Results for Lorundrostat In Uncontrolled and Treatment-Resistant Hypertension

By Charles Gross

September 10, 10:24 AM

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated

MLYS

Morgan Stanley Expects Solid Q1 Earnings From General Mills

By Shivani Kumaresan

September 13, 2:06 PM

Morgan Stanley analyst Pamela Kaufman has reiterated an Underweight rating on the shares of General Mills Inc (NYSE:GIS) with a price target of…

GIS

Credit Suisse Maintains Outperform on TransDigm Gr, Raises Price Target to $765

Related Posts

Why Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Nvidia CEO Jensen Huang Mesmerizes Analysts, Market Watchers With Computex Keynote: ‘Will Make You Want To Buy $NVDA’

Mineralys Therapeutics Announced JAMA Publication Of Full Target-HTN Phase 2 Trial Results for Lorundrostat In Uncontrolled and Treatment-Resistant Hypertension

Morgan Stanley Expects Solid Q1 Earnings From General Mills